Table 3.
Treatments received (%) | N (%) |
---|---|
Hydroxychloroquine | 31 (100) |
Lopinavir/ritonavir | 31 (100) |
Azithromycin | 26 (83.9) |
Remdesivir | 5 (16.1) |
Interferon | 1 (3.2) |
Steroid therapy | 18 (58.1) |
Steroid therapy prior to siltuximab | 11 (35.5) |
Tocilizumab | 8 (25.8) |
Tocilizumab prior to siltuximab | 7 (22.58) |
Days from tocilizumab administration to siltuximab (IQR) | 2 (1-3) |
Anakinra | 7 (22.6) |
Anakinra after siltuximab administration | 6 (19.4) |